<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30348123</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2407</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>22</Day>                    </PubDate>                </JournalIssue>                <Title>BMC cancer</Title>                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Statin use in cancer survivors versus the general population: cohort study using primary care data from the UK clinical practice research datalink.</ArticleTitle>            <Pagination>                <MedlinePgn>1018</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4947-8</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer survivors may be at increased risk of cardiovascular diseases, but little is known about whether prescribing guidelines for the primary prevention of cardiovascular disease are adequately implemented in these patients. We compared levels of statin initiation and cessation among cancer survivors compared to the general population to determine differences in uptake of pharmaceutical cardiovascular risk prevention measures in these groups.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The study population included individuals aged ≥40 during 2005-13 within the UK Clinical Practice Research Datalink primary care database. Within this population we identified cancer survivors who were alive and under follow-up at least 1 year after diagnosis, and controls with no cancer history. Follow-up time prior to cancer diagnosis was included in the control cohort. Using logistic regression, we compared these groups with respect to uptake of statins within 1 month of a first high recorded cardiovascular risk score. Then, we used Cox modelling to compare persistence on statin therapy (time to statin cessation) between cancer survivors and controls from the main study population who had initiated on a statin.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4202 cancer survivors and 113,035 controls with a record indicating a high cardiovascular risk score, 23.0% and 23.5% respectively initiated a statin within 1 month (adjusted odds ratio 0.98 [91.8-1.05], p = 0.626). Cancer survivors appeared more likely to discontinue statin treatment than controls (adjusted hazard ratio 1.07 [1.01-1.12], p = 0.02). This greater risk of discontinuing was only evident after the first year of therapy (p-interaction &lt; 0.001).</AbstractText>                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Although cardiovascular risk is thought to be higher in cancer survivors compared to the general population, cancer survivors were no more likely to receive statins, and marginally more likely to cease long-term therapy, than general population controls. There may be an opportunity to mitigate the suspected higher cardiovascular risk in the growing population of cancer survivors by improving uptake of lipid-lowering treatment and persistence on therapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chidwick</LastName>                    <ForeName>Kendal</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Strongman</LastName>                    <ForeName>Helen</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Matthews</LastName>                    <ForeName>Anthony</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stanway</LastName>                    <ForeName>Susannah</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Unit, Royal Marsden Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lyon</LastName>                    <ForeName>Alexander R</ForeName>                    <Initials>AR</Initials>                    <AffiliationInfo>                        <Affiliation>Imperial College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smeeth</LastName>                    <ForeName>Liam</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bhaskaran</LastName>                    <ForeName>Krishnan</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. krishnan.bhaskaran@lshtm.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>Wellcome Trust</Agency>                    <Country>United Kingdom</Country>                </Grant>                <Grant>                    <GrantID>107731/Z/15/Z</GrantID>                    <Agency>Wellcome Trust</Agency>                    <Country>United Kingdom</Country>                </Grant>                <Grant>                    <GrantID>107731/Z/15/Z</GrantID>                    <Agency>Royal Society</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>22</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Cancer</MedlineTA>            <NlmUniqueID>100967800</NlmUniqueID>            <ISSNLinking>1471-2407</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2015 Mar 14;385(9972):977-1010</RefSource>                <PMID Version="1">25467588</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Pharmacother. 2010 Sep;44(9):1410-21</RefSource>                <PMID Version="1">20702755</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2017 Nov 14;70(20):2536-2551</RefSource>                <PMID Version="1">29145954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tex Heart Inst J. 2012;39(2):190-8</RefSource>                <PMID Version="1">22740730</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol Pract. 2016 Aug;12(8):e800-9</RefSource>                <PMID Version="1">27407167</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Public Health (Oxf). 2015 Jun;37(2):234-40</RefSource>                <PMID Version="1">25326192</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ Open. 2016 Jan 13;6(1):e008840</RefSource>                <PMID Version="1">26762161</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2014 Aug 30;384(9945):755-65</RefSource>                <PMID Version="1">25129328</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2011 Jul 14;343:d4350</RefSource>                <PMID Version="1">21757438</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol. 2012 Oct;36(5):425-9</RefSource>                <PMID Version="1">22727737</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Palliat Med. 2013 Apr;16(4):412-8</RefSource>                <PMID Version="1">23305190</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Cardiol. 2016 Jul;32(7):871-80</RefSource>                <PMID Version="1">27179545</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Surviv. 2013 Jun;7(2):253-61</RefSource>                <PMID Version="1">23417882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2015 Mar 28;385(9974):1206-18</RefSource>                <PMID Version="1">25479696</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prev Med. 2015 Sep;78:1-8</RefSource>                <PMID Version="1">26051202</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2013 Jan 15;108(1):14-20</RefSource>                <PMID Version="1">23257892</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 Nov 1;25(31):4952-60</RefSource>                <PMID Version="1">17971593</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Atheroscler Rep. 2013 Jan;15(1):291</RefSource>                <PMID Version="1">23225173</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Epidemiol. 2015 Jun;44(3):827-36</RefSource>                <PMID Version="1">26050254</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011 Jun 20;13(3):R64</RefSource>                <PMID Version="1">21689398</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):168-75</RefSource>                <PMID Version="1">23239282</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 Sep 1;25(25):3991-4008</RefSource>                <PMID Version="1">17577017</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Soc Sci Med. 2015 Apr;131:280-8</RefSource>                <PMID Version="1">24954520</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2017 Nov 14;70(20):2552-2565</RefSource>                <PMID Version="1">29145955</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2016 Jun 28;353:i3305</RefSource>                <PMID Version="1">27353261</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Heart. 2013 Nov;99(21):1597-602</RefSource>                <PMID Version="1">23735939</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ Qual Saf. 2016 Oct;25(10):747-58</RefSource>                <PMID Version="1">26647412</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Gen Pract. 2015 Nov;65(640):e761-8</RefSource>                <PMID Version="1">26500324</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Apr 1;34(10):1122-30</RefSource>                <PMID Version="1">26834065</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Heart. 2005 Dec;91 Suppl 5:v1-52</RefSource>                <PMID Version="1">16365341</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cancer survivor</Keyword>            <Keyword MajorTopicYN="N">Cardiovascular risk</Keyword>            <Keyword MajorTopicYN="N">Persistence</Keyword>            <Keyword MajorTopicYN="N">Primary care</Keyword>            <Keyword MajorTopicYN="N">Statin</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30348123</ArticleId>            <ArticleId IdType="doi">10.1186/s12885-018-4947-8</ArticleId>            <ArticleId IdType="pii">10.1186/s12885-018-4947-8</ArticleId>            <ArticleId IdType="pmc">PMC6196462</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>